Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Wiskott-Aldrich syndrome in which the cause of the disease is a mutation in the WIPF1 gene.
Features include always present findings: Abnormal natural killer cell physiology, Recurrent infections, Eczematoid dermatitis, and Abnormal T cell proliferation and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 2 | Recurrent infections, Low platelet count (thrombocytopenia) |
WIPF1 function has not been fully characterized.
Wiskott-Aldrich syndrome 2 is caused by mutations in the WIPF1 gene on chromosome 2.
Genetic testing for WIPF1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Wiskott-Aldrich syndrome 2 has been reported in the published literature.
Phenotype severity distribution: 6 always present features.
No clinical trials have been registered for Wiskott-Aldrich syndrome 2.
71 publications have been identified in PubMed for Wiskott-Aldrich syndrome 2. Research spans Basic Science / Preclinical (51%), Review / Meta-Analysis (13%), and Epidemiology / Natural History (13%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 36 | 51% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:57 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Wiskott-Aldrich syndrome 2
Skin
1 |
Eczematoid dermatitis |
9 |
13% |
Disease patterns and progression | 9 | 13% |
Patient case studies | 7 | 10% |
Testing and diagnosis research | 4 | 6% |
New treatment approaches | 4 | 6% |
Other research | 1 | 1% |
Clinical study results | 1 | 1% |
Rayan MN (2026). [PMID: 41757399](https://pubmed.ncbi.nlm.nih.gov/41757399/). *Immun Inflamm Dis*. [Case Report / Case Series]
Mitra D (2026). [PMID: 41591360](https://pubmed.ncbi.nlm.nih.gov/41591360/). *J Cell Biol*. [Basic Science / Preclinical]
Alexander JL (2026). [PMID: 41346295](https://pubmed.ncbi.nlm.nih.gov/41346295/). *Blood Adv*. [Clinical Trial Publication]
Suri D (2026). [PMID: 42205538](https://pubmed.ncbi.nlm.nih.gov/42205538/). *J Hum Immun*. [Epidemiology / Natural History]
Razaghian A (2026). [PMID: 41718912](https://pubmed.ncbi.nlm.nih.gov/41718912/). *J Clin Immunol*. [Epidemiology / Natural History]
Tenney L (2026). [PMID: 41383448](https://pubmed.ncbi.nlm.nih.gov/41383448/). *Chem Sci*. [Diagnostic / Biomarker]
Midena F (2026). [PMID: 41512872](https://pubmed.ncbi.nlm.nih.gov/41512872/). *Cell Stem Cell*. [Epidemiology / Natural History]
He T (2026). [PMID: 41495793](https://pubmed.ncbi.nlm.nih.gov/41495793/). *Chin Med*. [Basic Science / Preclinical]
Ito N (2026). [PMID: 41731989](https://pubmed.ncbi.nlm.nih.gov/41731989/). *Intest Res*. [Epidemiology / Natural History]
Lu Y (2026). [PMID: 41608858](https://pubmed.ncbi.nlm.nih.gov/41608858/). *Elife*. [Basic Science / Preclinical]
AI-curated news mentioning Wiskott-Aldrich syndrome 2
Updated May 26, 2026
Recent research highlights large vessel vasculopathy as an underrecognized complication in Wiskott-Aldrich syndrome. This discovery may prompt further investigation into the cardiovascular risks associated with this rare genetic disorder.
FDA approves Waskyra (etuvetidigene autotemcel) as the first gene therapy for Wiskott-Aldrich syndrome. This landmark approval marks a significant advancement in the treatment options available for this rare immunodeficiency disorder.